Beta 3-adrenoceptors in the cardiovascular system

被引:13
作者
Gauthier, Chantal
Seze-Goismier, Camille
Rozec, Bertrand
机构
[1] INSERM, U533, Fac Med, Inst Thorax 1, F-44035 Nantes, France
[2] CHURU G & R Laennec, Dept Anesthesie & Reanimat Chirurg, Nantes, France
[3] Univ Nantes, Fac Sci & Tech, Nantes, France
关键词
beta 3-adrenergic receptors; beta-blocker; cardiovasular system; heart failure; hypertension;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The sympathetic system is central in the understanding of numerous physiological and physiopathological phenomena. During the last decade, the characterization of a new beta-adrenoceptor subtype, beta(3), in addition to beta(1) and beta(2)-adrenoceptor in the cardiovascular system has changed the view of the roles of the sympathetic system. In heart, beta(3)-adrenoceptor stimulation produce an opposite effect to that induced by beta(1) and beta(2)-adrenoceptors suggesting that in normal heart, the negative inotropic effect induced by the beta(3)-adrenergic stimulation might play a role of a "safety-valve" during intense adrenergic stimulation. In vessels, all beta-adrenoceptors subtypes, beta(1), beta(2) and beta(3), mediate a vasodilation. As beta(3)-adrenoceptors are activated at higher concentrations of catecholamines than beta(1) and beta(2)-adrenoceptors, they could play the roll of a receptor reserve. beta(3)-adrenoceptors are overexpressed in heart failure and hypertension and could constitute a new therapeutic target. In addition, the efficiency of some beta-blockers such as nebivolol could result from an action on beta(3)-adrenoceptors.
引用
收藏
页码:193 / 204
页数:12
相关论文
共 74 条
[1]
β3-adrenoceptor agonists:: potential, pitfalls and progress [J].
Arch, JRS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 440 (2-3) :99-107
[2]
ATYPICAL BETA-ADRENOCEPTOR ON BROWN ADIPOCYTES AS TARGET FOR ANTI-OBESITY DRUGS [J].
ARCH, JRS ;
AINSWORTH, AT ;
CAWTHORNE, MA ;
PIERCY, V ;
SENNITT, MV ;
THODY, VE ;
WILSON, C ;
WILSON, S .
NATURE, 1984, 309 (5964) :163-165
[3]
In situ assessment of the role of the beta(1)-, beta(2)- and beta(3)-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue [J].
Barbe, P ;
Millet, L ;
Galitzky, J ;
Lafontan, M ;
Berlan, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (05) :907-913
[4]
INVITRO INHIBITION OF INTESTINAL MOTILITY BY PHENYLETHANOLAMINOTETRALINES - EVIDENCE OF ATYPICAL BETA-ADRENOCEPTORS IN RAT COLON [J].
BIANCHETTI, A ;
MANARA, L .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 100 (04) :831-839
[5]
BLIN N, 1993, MOL PHARMACOL, V44, P1094
[6]
Nitric oxide synthase expression and role during cardiomyogenesis [J].
Bloch, W ;
Fleischmann, BK ;
Lorke, DE ;
Andressen, C ;
Hops, B ;
Hescheler, J ;
Addicks, K .
CARDIOVASCULAR RESEARCH, 1999, 43 (03) :675-684
[7]
β3-Adrenergic regulation of an ion channel in the heart -: inhibition of the slow delayed rectifier potassium current IKs in guinea pig ventricular myocytes [J].
Bosch, RF ;
Schneck, AC ;
Kiehn, J ;
Zhang, W ;
Hambrock, A ;
Eigenberger, BW ;
Rüb, N ;
Gogel, J ;
Mewis, C ;
Seipel, L ;
Kühlkamp, V .
CARDIOVASCULAR RESEARCH, 2002, 56 (03) :393-403
[8]
BETA-1-ADRENERGIC-RECEPTOR AND BETA-2-ADRENERGIC-RECEPTOR SUBPOPULATIONS IN NONFAILING AND FAILING HUMAN VENTRICULAR MYOCARDIUM - COUPLING OF BOTH RECEPTOR SUBTYPES TO MUSCLE-CONTRACTION AND SELECTIVE BETA-1-RECEPTOR DOWN-REGULATION IN HEART-FAILURE- [J].
BRISTOW, MR ;
GINSBURG, R ;
UMANS, V ;
FOWLER, M ;
MINOBE, W ;
RASMUSSEN, R ;
ZERA, P ;
MENLOVE, R ;
SHAH, P ;
JAMIESON, S ;
STINSON, EB .
CIRCULATION RESEARCH, 1986, 59 (03) :297-309
[9]
Candelore MR, 1999, J PHARMACOL EXP THER, V290, P649
[10]
The tissue distribution of the human β3-adrenoceptor studied using a monoclonal antibody:: Direct evidence of the β3-adrenoceptor in human adipose tissue, atrium and skeletal muscle [J].
Chamberlain, PD ;
Jennings, KH ;
Paul, F ;
Cordell, J ;
Berry, A ;
Holmes, SD ;
Park, J ;
Chambers, J ;
Sennitt, MV ;
Stock, MJ ;
Cawthorne, MA ;
Young, PW ;
Murphy, GJ .
INTERNATIONAL JOURNAL OF OBESITY, 1999, 23 (10) :1057-1065